Cost-effective control of chronic viral diseases: Finding the optimal level of screening and contact tracing

Mathematical Biosciences

Volumn 224, Issue 1, 2010, Pages 35-42

  Armbruster, Benjamin ^a   Brandeau, Margaret L ^b  

^a Northwestern University   (United States)

^b Stanford University   (United States)

Author keywords

Chronic viral disease; Compartmental model; Contact tracing; Cost effectiveness

Indexed keywords

ANTIVIRAL TREATMENTS; CAPACITY LIMITATION; CLOSE APPROXIMATION; COMPARTMENTAL MODEL; CONTACT TRACING; HEALTH BENEFITS; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INCREMENTAL COST; INFECTIOUS DISEASE; MAXIMAL RATES; OPTIMAL CONTROL PROBLEM; OPTIMAL LEVEL; OPTIMAL SOLUTIONS; OPTIMAL STRATEGIES; PUBLIC HEALTH; VIRAL DISEASE;

COST EFFECTIVENESS; COSTS; OPTIMAL SYSTEMS; OPTIMIZATION; VIRUSES;

DISEASES;

COST; DISEASE CONTROL; DISEASE PREVALENCE; DISEASE TREATMENT; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; MODELING; PUBLIC HEALTH; VIRAL DISEASE;

ARTICLE; CASE FINDING; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARTMENT MODEL; CONTACT EXAMINATION; CONTROL STRATEGY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; HEALTH BEHAVIOR; HEPATITIS B; HEPATITIS B VIRUS; INFECTION CONTROL; MATHEMATICAL COMPUTING; PROCESS DEVELOPMENT; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; VIRUS INFECTION;

ALGORITHMS; ASIAN AMERICANS; CHRONIC DISEASE; COMMUNICABLE DISEASE CONTROL; CONTACT TRACING; COST-BENEFIT ANALYSIS; HEPATITIS B; HUMANS; MASS SCREENING; MODELS, BIOLOGICAL; OCEANIC ANCESTRY GROUP; PREVALENCE; UNITED STATES; VIRUS DISEASES;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 75549091123     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mbs.2009.12.006     Document Type: Article

References (41)

1. AB 158, Medi-Cal: benefits for nondisabled persons infected with chronic hepatitis B, 2008, Proposed California legislation, Available from: URL http://www.aroundthecapitol.com/Bills/AB_158.
2. Armbruster B., Brandeau M.L. Contact tracing to control infectious disease: when enough is enough. Health Care Manage. Sci. 2007, 10(4):341-355. Available from: URL http://users.iems.northwestern.edu/~armbruster/HCMS2007.pdf.
3. Armbruster B., Brandeau M.L. Optimal mix of screening and contact tracing for endemic diseases. Math. Biosci. 2007, 209(2):386.
4. Brandeau M.L., Zaric G.S., Richter A. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis. J. Health Econ. 2003, 22(4):575. Available from: http://dx.doi.org/10.1016/S0167-6296(03)00043-2.
5. Brooks E.A., Lacey L.F., Payne S.L., Miller D.W. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am. J. Manag. Care 2001, 7(7):677.
6. CDC, Disease burden from hepatitis A, B, and C in the United States, 2008a, Available from: URL http://www.cdc.gov/hepatitis/Statistics.htm.
7. CDC, Hepatitis B FAQs for health professionals, 2008b, URL Available from: http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm.
8. CDC, Prevention of specific infectious diseases, 2008c, In CDC Health Information for International Travel 2008, Chapter 4, Available from: URL http://wwwn.cdc.gov/travel/contentYellowBook.aspx.
9. CDC, Surveillance for acute viral hepatitis - United States, 2006, MMWR, 57, 2008d, Available from: URL http://www.cdc.gov/mmwr/PDF/ss/ss5702.pdf.
10. DHS, Profiles on legal permanent residents: 2007, 2008, Available from: URL http://www.dhs.gov/ximgtn/statistics/data/DSLPR07c.shtm.
11. E.A. Enns, M.L. Brandeau, T.K. Igeme, E. Bendavid, Assessing effectiveness and cost-effectiveness of concurrency reduction for HIV prevention, Working Paper, Stanford University, 2009.
12. Freedberg K.A., Losina E., Weinstein M.C., Paltiel A.D., Cohen C.J., Seage G.R., Craven D.E., Zhang H., Kimmel A.D., Goldie S.J. The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 2001, 344(11):824. Available from: URL http://content.nejm.org/cgi/content/abstract/344/11/824.
13. Gold M., Siegel J., Russell L., Weinstein M. Cost-Effectiveness in Health and Medicine 1996, Oxford University Press.
14. Grass D., Caulkins J.P., Feichtinger G., Behrens D.A. Optimal Control of Nonlinear Processes: With Applications in Drugs, Corruption and Terror 2008, Springer.
15. Halloran M.E., Ferguson N.M., Eubank S., Longini I.M., Cummings D.A.T., Lewis B., Xu S., Fraser C., Vullikanti A., Germann T.C., Wagener D., Beckman R., Kadau K., Barrett C., Macken C.A., Burke D.S., Cooley P. Modeling targeted layered containment of an influenza pandemic in the United States. Proc. Natl. Acad. Sci. USA 2008, 105(12):4639. Available from: URL http://dx.doi.org/10.1073/pnas.0706849105.
16. Hethcote H.W., Ark J.W.V., Karon J.M. A simulation model of AIDS in San Francisco: II. Simulations, therapy, and sensitivity analysis. Math. Biosci. 1991, 106(2):223. Available from: URL http://www.sciencedirect.com/science/article/B6VHX-45F52P8-KP/2/4a113da0514d6c361439fdcdaca2594d.
17. Hutton D.W., Tan D., So S.K., Brandeau M.L. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann. Int. Med. 2007, 147(7):460. Available from: URL http://www.annals.org/cgi/content/abstract/147/7/460.
18. Kanwal F., Gralnek I.M., Martin P., Dulai G.S., Farid M., Spiegel B.M.R. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann. Int. Med. 2005, 142(10):821.
19. Lin S.Y., Chang E.T., So S.K. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology 2007, 46(4):1034. Available from: http://dx.doi.org/10.1002/hep.21784.
20. Long E., Vaidya N., Brandeau M. Controlling co-epidemics: analysis of HIV and tuberculosis infection dynamics. Oper. Res. 2008, 56:1366.
21. Mas-Collel A., Whinston M.D., Green J.R. Microeconomic Theory 1995, Oxford University Press, (Chapter 3).
22. Morris M., Kretzschmar M. Concurrent partnerships and the spread of HIV. AIDS 1997, 11(5):641.
23. Owens D.K. Interpretation of cost-effectiveness analyses. J. Gen. Int. Med. 1998, 13:716.
24. Porco T.C., Small P.M., Blower S.M. Amplification dynamics: predicting the effect of HIV on tuberculosis outbreaks. J. Acquir. Immune Defic. Syndr. 2001, 28(5):437.
25. Quinn T., Wawer M., Sewankambo N., Serwadda D., Li C., Wabwire-Mangen F., Meehan M., Lutalo T., Gray R. Viral load and heterosexual transmission of human immunodeficiency virus type 1. New Eng. J. Med. 2000, 342(13):921.
26. Revelle C., Feldmann F., Lynn W. An optimization model of tuberculosis epidemiology. Manage. Sci. 1969, 16(4):B190. Available from: URL http://www.jstor.org/stable/2628798.
27. Sanders J.L. Quantitative guidelines for communicable disease control programs. Biometrics 1971, 27(4):883. Available from: URL http://www.jstor.org/stable/2528825.
28. Sethi S.P. Quantitative guidelines for communicable disease control program: a complete synthesis. Biometrics 1974, 30(4):681. Available from: URL http://www.jstor.org/stable/2529232.
29. Shepherd J., Jones J., Takeda A., Davidson P., Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol. Assess. 2006, 10(28):1.
30. Taylor H.M. Some models in epidemic control. Math. Biosci. 1968, 3:383.
31. UNAIDS, Resource needs for an expanded response to AIDS in low- and middle-income countries, 2005, Available from: URL http://www.unaids.org/html/pub/publications/irc-pub06/resourceneedsreport_24jun05_en_pdf.pdf.
32. UNAIDS, 2006 report on the global AIDS epidemic, 2006.
33. US Census Bureau, General demographic characteristics, 2006.
34. US Census Bureau, 2007 American community survey, 2007.
35. Velasco-Hernández J.X., Brauer F., Castillo-Chavez C. Effects of treatment and prevalence-dependent recruitment on the dynamics of a fatal disease. IMA J. Math. Appl. Med. Biol. 1996, 13(3):175.
36. WHO, Health situation and trends assessment: health situation in the South-East Asia region, 1998-2000, 2001, Available from: URL http://www.searo.who.int/en/Section1243/Section1382/Section1386/Section1898.htm.
37. WHO, Western Pacific regional plan for hepatitis B control through immunization, 2007, Available from: URL http://www.wpro.who.int/NR/rdonlyres/CEDD5D4E-71BE-49F4-AEEC-1384751598EE/0/POA_HepB.pdf.
38. Zaric G.S. Resource allocation for control of infectious disease epidemics. Comm. Theor. Biol. 2003, 8:475.
39. Zaric G.S., Brandeau M.L. Resource allocation for epidemic control over short time horizons. Math. Biosci. 2001, 171:33.
40. Zaric G.S., Brandeau M.L. Dynamic resource allocation for epidemic control in multiple populations. IMA J. Math. Appl. Med. Biol. 2002, 19:235.
41. I. Zeiler, Optimal Dynamic Control with DNSS Curves: Multiple Equilibria in Epidemic Models of HIV/AIDS and Illicit Drug Use, Ph.D. thesis, Vienna University of Technology, 2008.